NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

Rhea-AI Summary

NanoViricides (NYSE American: NNVC) will participate in the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York City. Anil R. Diwan, PhD, President & Exec. Chairman, will host one-on-one meetings from 9:45 A.M. to 2:45 P.M. ET.

Interested parties should contact the DBC Conference Team to register for meetings.

Market Context

This announcement highlights NNVC’s participation in the D. Boral Capital Global Conference on May 7...

Analysis

This announcement highlights NNVC’s participation in the D. Boral Capital Global Conference on May 7, 2026, continuing a pattern of investor outreach alongside NV-387 development. Recent history shows notable price reactions to clinical and regulatory milestones, such as gains of 15.38% and 18.32% on key NV-387 updates. At the same time, SEC filings disclose net losses, going-concern language, and use of an effective S-3 and warrant structures for capital. Investors may watch for future clinical progress and additional financing steps.

Key Figures

Conference date: May 7, 2026 Meeting window: 9:45 A.M.–2:45 P.M. (ET)

2 metrics

Conference date May 7, 2026 D. Boral Capital Global Conference at The Plaza Hotel, New York City

Meeting window 9:45 A.M.–2:45 P.M. (ET) One-on-one meetings hosted by Anil R. Diwan at the conference

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Orphan designation	Positive	+15.4%	NV-387 received US FDA Orphan Drug Designation for measles.
Apr 21	Disease context update	Positive	-1.6%	Company highlighted measles outbreaks and positioned NV-387 as candidate treatment.
Apr 07	RPDD application	Positive	+6.9%	Filed Rare Pediatric Disease Drug designation application for NV-387 in measles.
Apr 01	Phase II trial plan	Positive	+4.7%	Announced upcoming Phase II clinical trial of NV-387 for MPox.
Mar 11	Conference & manufacturing	Positive	+18.3%	Investor conference participation and completion of Phase II NV-387 oral gummies manufacture.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinically focused and designation-related updates for NV-387 often saw positive price reactions, though not uniformly.

Recent Company History

Over recent months, NNVC news has centered on its antiviral NV-387 and capital markets activity. On May 4, 2026, Orphan Drug Designation for measles drove a 15.38% gain. Earlier measles-related communications on April 21 saw a modest -1.56% move, while a Rare Pediatric Disease application on April 7 corresponded to a 6.93% rise. Phase II plans for MPox on April 1 and a March investor conference plus Phase II product readiness on March 11 led to gains of 4.66% and 18.32%, respectively. Today’s routine conference participation fits this ongoing investor-relations cadence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7, 2026, at The Plaza Hotel in New York City.

Anil R. Diwan, PhD, President & Exec. Chairman will be hosting one-on-one meetings on May 7th from 9:45 A.M. to 2:45 P.M. (ET).

To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact the DBC Conference Team at dbcconferenceteam@dboralcapital.com.

About NanoViricides, Inc.

NanoViricides, Inc., is a publicly traded company (NYSE American: NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape. Its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an “Orphan Drug Designation” (ODD) by the US FDA Office of Orphan Products Development (OOPD). This could lead to could provide 7 years market exclusivity, tax credits for clinical trial costs, and fee exemptions upon approval. NV-387 is a revolutionary antiviral that we believe will be the drug offered at “ first visit” when the patient presents to a doctor with any respiratory viral illness. NV-387 was also found to be highly effective in lethal animal infection models of Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $35 billion in capital since its inception in 2020, executing ~400 transactions across a broad range of investment banking products.

For further information:
Meeta R Vyas
CFO
‭+1 (203) 937-6137‬
info@nanoviricides.com 
www.nanoviricides.com

Source NanoViricides, Inc.

FAQ

When will NanoViricides (NNVC) attend the D. Boral Capital Global Conference?

NanoViricides will attend on May 7, 2026. According to the company, management will be on-site at The Plaza Hotel in New York City for meetings and investor engagement that day.

Who from NanoViricides (NNVC) will hold investor meetings at the conference?

Anil R. Diwan, PhD, President & Executive Chairman will host one-on-one meetings. According to the company, he is scheduled to meet investors from 9:45 A.M. to 2:45 P.M. ET on May 7, 2026.

How can investors register for one-on-one meetings with NanoViricides (NNVC) at the conference?

Investors should contact the DBC Conference Team to register for meetings. According to the company, interested parties can email dbcconferenceteam@dboralcapital.com to arrange one-on-one meetings on May 7, 2026.

Where is NanoViricides (NNVC) hosting meetings during the D. Boral Capital Global Conference?

Meetings will be held at The Plaza Hotel, New York City. According to the company, one-on-one sessions with management are scheduled there on May 7, 2026, during the conference.

What are the scheduled meeting times for NanoViricides (NNVC) management at the conference?

One-on-one meetings are set from 9:45 A.M. to 2:45 P.M. ET on May 7, 2026. According to the company, Anil R. Diwan will be available during those specific times for investor meetings.